Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 06, 2025 03:53 ET
|
Oculis Holding AG
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...
Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða
January 06, 2025 03:47 ET
|
Oculis Holding AG
ZUG, Sviss, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 var öruggt og þoldist vel í samanburði við lyfleysu.Tölfræðilega marktækar framfarir á virkni samanborið við lyfleysu, m.a. fyrir þykkt sjónhimnu...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 06, 2025 03:47 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy...
Oculis Publishes Notification of Major Changes in Voting Rights
January 03, 2025 18:48 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
December 06, 2024 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Attachments
...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
November 29, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
November 27, 2024 04:15 ET
|
Oculis Holding AG
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the...
Oculis to Present at the Stifel 2024 Healthcare Conference
November 13, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis to Present at the Stifel 2024 Healthcare Conference
November 13, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
November 07, 2024 04:00 ET
|
Oculis Holding AG
Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout...